1. P805 Selnoflast, a potent NLRP3 inhibitor - results from a phase 1b experimental medicine study in patients with Ulcerative Colitis. (30th January 2023) Authors: Klughammer, B; Piali, L; Nica, A C; Nagel, S; Bailey, L; Jochum, C; Ignatenko, S; Bläuer, A; Danilin, S; Gulati, P; Hayward, J; Scepanovic, P; Retout, S; Zhang, J D; Bhosale, S; Sue-Ling, K; Chong, C F; Christ, A Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗